Chronic Kidney Disease (CKD) Drugs Market Overview
Chronic kidney disease is associated with a number of clinical patterns. Kidneys play a crucial role in ensuring timely and healthy urination, and disorders of the kidneys disturb this functionality. Furthermore, kidney problems can disrupt people's sleeping and eating habits, opening up new growth prospects in the chronic kidney disease (CKD) drugs market. In recent years, several novel medications to treat renal problems have been created. The chronic kidney disease (CKD) drugs market will see an increase in demand as a result of this trend.
The global chronic kidney disease drug market is being propelled forward by important reasons such as the rising prevalence of chronic kidney disease among patients around the world. The desire for novel treatments to improve the quality of life of patients is increasing as the frequency of chronic renal disease rises. According to Centers for Disease Control and Prevention, More than 1 in 7, that is 15% of US adults or 37 million people, are estimated to have CKD. Furthermore, the growing elderly population is a major driver of market expansion, as people over the age of 60 are more susceptible to different ailments, including chronic renal disease. As a result, increased research and development activities in the creation of chronic kidney disease drugs are expected to drive market expansion.
However, some restrictions are limiting the global chronic kidney disease drug market growth. Factors such as the rising popularity of generic drugs are posing a significant challenge to the global market. In addition, poor patient compliance in some countries is likely to hinder the global market for chronic kidney disease drugs.
| Report Metric | Details |
| Market size available for years | 2023–2030 |
| Base year considered | 2023 |
| Forecast period | 2024–2030 |
| Forecast unit | Value (USD Million) |
| Segments covered | Drug Class, End-User, and Region. |
| Regions covered | North America (the U.S. and Canada), Europe (UK, Germany, France, Italy, Spain, Russia, Rest of Europe), Asia-Pacific (China, India, Japan, Australia, South East Asia, Rest of Asia Pacific), Latin America and the Middle East and Africa (Brazil, Saudi Arabia, UAE, Rest of LAMEA) |
| Companies covered | F. Hoffmann-La Roche Ltd., Pfizer Inc., Sanofi S.A., GlaxoSmithKline Plc, Kissei Pharmaceutical Co. Ltd., AbbVie Inc. |
Covid-19 Impact on Chronic Kidney Disease (CKD) Drugs Market
In addition, the current Chronic Kidney Disease (CKD) Drugs Market study offers a detailed analysis of the current COVID-19 pandemic impact on the market growth and its influence on the future growth of the Chronic Kidney Disease (CKD) Drugs Market. The recently published report demonstrates the elevation in the demand for the healthcare sector. The healthcare manufacturers have experienced long term as well as short term effect which includes supply shortages, panic buying, and stocking, regulation changes as short-term whereas approval delays and possible trend variations in consumption could be perceived as long-term impacts of COVID-19 on the health and pharmaceutical market.
The increasing need for a cure has pushed vaccine research and manufacturers to the limit. In addition to this, panic conditions have already spurred the demand for many healthcare products and services which are discussed in detail in this report. Moreover, the impact of COVID-19 on overall market revenue for the base year 2020 and its projection up to 2027 is provided in detail in this report.
Chronic Kidney Disease (CKD) Drugs Market Segment Overview
Based on Drug Class, the Calcium Channel Blockers segment holds the largest share in the global Chronic Kidney Disease (CKD) Drugs market. This is because it is mostly used in the treatment of chronic kidney disease. Furthermore, the calcium channel blockers improve the symptoms in several conditions such as coronary artery diseases, and high blood pressure. According to End-User, the hospital’s segment accounted for the major market share compared to specialty clinics. This is due to the availability of technologically advanced diagnostic equipment for the early diagnosis of the condition.
Chronic Kidney Disease (CKD) Drugs Market, By Drug Class
· ACE Inhibitors
· Angiotensin-II receptor blockers
· Beta-blockers
· Calcium channel blockers
· Diuretics
· Erythropoiesis-stimulating agents (ESAs)
· Others
Chronic Kidney Disease (CKD) Drugs Market, By End-User
· Hospitals
· Specialty Clinics
Chronic Kidney Disease (CKD) Drugs Market Regional Overview
Based on the region, North America is at the forefront and is predicted to continue to retain its lead position through the forecast period. The presence of the majority of chronic kidney disease drug producers in the region is credited with the region's dominance. In recent years, the healthcare sector in the United States has seen a rise in revenue, owing mostly to new investments. The market's growth and maturity have been aided by an emphasis on treating renal problems, particularly among the elderly. On the other hand, the Asia Pacific region is rapidly expanding due to the vast number of renal disease patients and increased awareness of the disease.
Chronic Kidney Disease (CKD) Drugs Market, By Geography
· North America (US & Canada)
· Europe (UK, Germany, France, Italy, Spain, Russia & Rest of Europe)
· Asia-Pacific (Japan, China, India, Australia, & South Korea, & Rest of Asia-Pacific)
· LAMEA (Brazil, Saudi Arabia, UAE & Rest of LAMEA)
Chronic Kidney Disease (CKD) Drugs Market, Key Players
· F. Hoffmann-La Roche Ltd.
· Pfizer Inc.
· Sanofi S.A.
· GlaxoSmithKline Plc
· Kissei Pharmaceutical Co. Ltd.
· AbbVie Inc.
Frequently Asked Questions (FAQ) :
Q1. What are the driving factors for the global Chronic Kidney Disease (CKD) Drugs market?
The global chronic kidney disease drug market is being propelled forward by important reasons such as the rising prevalence of chronic kidney disease among patients around the world.
Q2. What are the restraining factors for the global Chronic Kidney Disease (CKD) Drugs market?
Factors such as the rising popularity of generic drugs are posing a significant challenge to the global market
Q3. Which segment is projected to hold the largest share in the global Chronic Kidney Disease (CKD) Drugs market. ?
Calcium Channel Blockers segment is projected to hold the largest share in the global Chronic Kidney Disease (CKD) Drugs market
Q4. Which region holds the largest share in the global Chronic Kidney Disease (CKD) Drugs market?
North America held the largest share in the global Chronic Kidney Disease (CKD) Drugs market.
Q5. Which are the prominent players in the global Chronic Kidney Disease (CKD) Drugs market?
F. Hoffmann-La Roche Ltd., Pfizer Inc., Sanofi S.A., GlaxoSmithKline Plc, Kissei Pharmaceutical Co. Ltd., AbbVie Inc. are some key players in the global Chronic Kidney Disease (CKD) Drugs market
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
4. Key Insights
- 4.1. Key Emerging Trends – For Major Countries
- 4.2. Latest Technological Advancement
- 4.3. Regulatory Landscape
- 4.4. Industry SWOT Analysis
- 4.5. Porters Five Forces Analysis
5. Global Chronic Kidney Disease (CKD) Drugs Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 5.1. Key Findings / Summary
- 5.2. Market Analysis, Insights and Forecast – By Drug Class
- 5.2.1. ACE Inhibitors
- 5.2.2. Angiotensin-II receptor blockers
- 5.2.3. Beta-blockers
- 5.2.4. Calcium channel blockers
- 5.2.5. Diuretics
- 5.2.6. Erythropoiesis-stimulating agents (ESAs)
- 5.2.7. Others
- 5.3. Market Analysis, Insights and Forecast – By End-User
- 5.3.1. Hospitals
- 5.3.2. Specialty Clinics
- 5.4. Market Analysis, Insights and Forecast – By Region
- 5.4.1. North America
- 5.4.2. Europe
- 5.4.3. Asia Pacific
- 5.4.4. Latin America, Middle East and Africa
6. North America Chronic Kidney Disease (CKD) Drugs Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 6.1. Key Findings / Summary
- 6.2. Market Analysis, Insights and Forecast – By Drug Class
- 6.2.1. ACE Inhibitors
- 6.2.2. Angiotensin-II receptor blockers
- 6.2.3. Beta-blockers
- 6.2.4. Calcium channel blockers
- 6.2.5. Diuretics
- 6.2.6. Erythropoiesis-stimulating agents (ESAs)
- 6.2.7. Others
- 6.3. Market Analysis, Insights and Forecast – By End-User
- 6.3.1. Hospitals
- 6.3.2. Specialty Clinics
- 6.4. Market Analysis, Insights and Forecast – By Country
- 6.4.1. U.S.
- 6.4.2. Canada
7. Europe Chronic Kidney Disease (CKD) Drugs Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 7.1. Key Findings / Summary
- 7.2. Market Analysis, Insights and Forecast – By Drug Class
- 7.2.1. ACE Inhibitors
- 7.2.2. Angiotensin-II receptor blockers
- 7.2.3. Beta-blockers
- 7.2.4. Calcium channel blockers
- 7.2.5. Diuretics
- 7.2.6. Erythropoiesis-stimulating agents (ESAs)
- 7.2.7. Others
- 7.3. Market Analysis, Insights and Forecast – By End-User
- 7.3.1. Hospitals
- 7.3.2. Specialty Clinics
- 7.4. Market Analysis, Insights and Forecast – By Country
- 7.4.1. UK
- 7.4.2. Germany
- 7.4.3. France
- 7.4.4. Italy
- 7.4.5. Spain
- 7.4.6. Russia
- 7.4.7. Rest of Europe
8. Asia Pacific Chronic Kidney Disease (CKD) Drugs Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 8.1. Key Findings / Summary
- 8.2. Market Analysis, Insights and Forecast – By Drug Class
- 8.2.1. ACE Inhibitors
- 8.2.2. Angiotensin-II receptor blockers
- 8.2.3. Beta-blockers
- 8.2.4. Calcium channel blockers
- 8.2.5. Diuretics
- 8.2.6. Erythropoiesis-stimulating agents (ESAs)
- 8.2.7. Others
- 8.3. Market Analysis, Insights and Forecast – By End-User
- 8.3.1. Hospitals
- 8.3.2. Specialty Clinics
- 8.4. Market Analysis, Insights and Forecast – By Country
- 8.4.1. China
- 8.4.2. India
- 8.4.3. Japan
- 8.4.4. Australia
- 8.4.5. South East Asia
- 8.4.6. Rest of Asia Pacific
9. Latin America, Middle East and Africa Chronic Kidney Disease (CKD) Drugs Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 9.1. Key Findings / Summary
- 9.2. Market Analysis, Insights and Forecast – By Drug Class
- 9.2.1. ACE Inhibitors
- 9.2.2. Angiotensin-II receptor blockers
- 9.2.3. Beta-blockers
- 9.2.4. Calcium channel blockers
- 9.2.5. Diuretics
- 9.2.6. Erythropoiesis-stimulating agents (ESAs)
- 9.2.7. Others
- 9.3. Market Analysis, Insights and Forecast – By End-User
- 9.3.1. Hospitals
- 9.3.2. Specialty Clinics
- 9.4. Market Analysis, Insights and Forecast – By Country
- 9.4.1. Brazil
- 9.4.2. Saudi Arabia
- 9.4.3. UAE
- 9.4.4. Rest of LAMEA
10. Competitive Analysis
- 10.1. Company Market Share Analysis, 2018
- 10.2. Key Industry Developments
- 10.3. Company Profile
- 10.4. F. Hoffmann-La Roche Ltd.
- 10.4.1. Business Overview
- 10.4.2. Segment 1 & Service Offering
- 10.4.3. Overall Revenue
- 10.4.4. Geographic Presence
- 10.4.5. Recent Development
- 10.5. Pfizer Inc.
- 10.6. Sanofi S.A.
- 10.7. GlaxoSmithKline Plc
- 10.8. Kissei Pharmaceutical Co. Ltd.
Data Library Research are conducted by industry experts who offer insight on industry structure, market segmentations technology assessment and competitive landscape (CL), and penetration, as well as on emerging trends. Their analysis is based on primary interviews (~ 80%) and secondary research (~ 20%) as well as years of professional expertise in their respective industries. Adding to this, by analysing historical trends and current market positions, our analysts predict where the market will be headed for the next five years. Furthermore, the varying trends of segment & categories geographically presented are also studied and the estimated based on the primary & secondary research.
In this particular report from the supply side Data Library Research has conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and SOFT) of the companies that active & prominent as well as the midsized organization
FIGURE 1: DLR RESEARH PROCESS
Extensive primary research was conducted to gain a deeper insight of the market and industry performance. The analysis is based on both primary and secondary research as well as years of professional expertise in the respective industries.
In addition to analysing current and historical trends, our analysts predict where the market is headed over the next five years.
It varies by segment for these categories geographically presented in the list of market tables. Speaking about this particular report we have conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and many more) of the major players active in the market.
Secondary ResearchSecondary research was mainly used to collect and identify information useful for the extensive, technical, market-oriented, and Friend’s study of the Global Extra Neutral Alcohol. It was also used to obtain key information about major players, market classification and segmentation according to the industry trends, geographical markets, and developments related to the market and technology perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, sec filings, journals, white papers, SOFT presentations, and company web sites.
Market Size EstimationBoth, top-down and bottom-up approaches were used to estimate and validate the size of the Global market and to estimate the size of various other dependent submarkets in the overall Extra Neutral Alcohol. The key players in the market were identified through secondary research and their market contributions in the respective geographies were determined through primary and secondary research.
Forecast Model
